Organon Announces Appointment of Herm Cukier as Executive Vice President of Global Marketing

ROSELAND, N.J., Sept. 26  /PRNewswire/ -- Organon, the human health care business unit of Akzo Nobel, is pleased to announce the appointment of Mr. Herm Cukier as Executive Vice President of Global Marketing.  Based in Roseland, New Jersey, Mr. Cukier will lead worldwide marketing activities and have direct responsibility for all late stage new product development teams. In addition, Mr. Cukier will be a member of the Organon Management Team.

"I am very excited to join Organon, an organization recognized around the world for its success and leadership in areas such a Psychiatric Disorders, Women's Health, Anesthesia, and Fertility.  I look forward to helping drive greater success with our already leading products and by bringing to market new products from a strong pipeline in these therapeutic categories," stated Mr. Cukier.

Mr. Cukier brings extensive pharmaceutical marketing experience to Organon.  He was most recently an executive with Bristol Myers Squibb and previously worked at Pfizer.  Mr. Cukier holds an MBA from the Columbia Business School and a BSE in bioengineering from the University of Pennsylvania.

Organon -- with shared head offices in Roseland, New Jersey, U.S.A. and Oss, The Netherlands -- creates, manufactures and markets prescription medicines that improve the health and quality of human life. Through a combination of independent growth and business partnerships, Organon strives to remain or become one of the leading pharmaceutical companies in each of its core therapeutic fields: reproductive medicine, psychiatry and anesthesia. Organon products are sold in over 100 countries, of which more than 60 have an Organon subsidiary. Organon is the human health care business unit of Akzo Nobel. Additional information about Organon is available through its corporate website, http://www.organon.com/.

Safe Harbor Statement*

This report contains statements which address such key issues as Organon's growth strategy, future financial results, market positions, product development, pharmaceutical products in the pipeline, and product approvals. Such statements, including but not limited to the "Outlook," should be carefully considered, and it should be understood that many factors could cause forecasted and actual results to differ from these statements. These factors include, but are not limited to price fluctuations, currency fluctuations, developments in raw material and personnel costs, pensions, physical and environmental risks, legal issues, and legislative, fiscal, and other regulatory measures. These factors also include changes in regulations or interpretations related to the implementation and reporting under IFRS, decisions to apply a different option of presentation permitted by IFRS, and various other factors related to the implementation of IFRS, including the implementation of IAS 32 and 39 for financial instruments. Stated competitive positions are based on management estimates supported by information provided by specialized external agencies.

For a more complete discussion of the risk factors affecting our business please see the Akzo Nobel Annual Report on Form 20-F filed with the United States Securities and Exchange Commission, a copy of which can be found on the Company's website http://www.akzonobel.com/.

* Pursuant to the U.S. Private Securities Litigation Reform Act 1995. 

DATASOURCE: Organon



CONTACT:  Frances DeSena of Organon Pharmaceuticals USA Inc.,

[phone]



Web site:  http://www.organon.com/

http://www.akzonobel.com/ 

Copyright